152 related articles for article (PubMed ID: 35514196)
1. Clinical significance of IDC-P as predictive factor after intensity-modulated radiation therapy.
Aizawa R; Tsuzuki T; Haga H; Nakamura K; Ogata T; Inoue T; Kobayashi T; Akamatsu S; Goto T; Ogawa O; Mizowaki T
Cancer Sci; 2022 Jul; 113(7):2425-2433. PubMed ID: 35514196
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of disease progression in younger men: Analysis of factors predicting biochemical failure and castration-resistant prostate cancer after high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Urol Oncol; 2021 Feb; 39(2):131.e9-131.e15. PubMed ID: 33127301
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis.
Miyajima K; Sato S; Uchida N; Suzuki H; Iwatani K; Imai Y; Aikawa K; Yanagisawa T; Kimura S; Tashiro K; Tsuzuki S; Honda M; Koike Y; Miki J; Miki K; Shimomura T; Yuen S; Yamada Y; Aoki M; Takahashi H; Urabe F; Kimura T
Clin Genitourin Cancer; 2024 Apr; 22(2):149-156.e1. PubMed ID: 38007354
[TBL] [Abstract][Full Text] [Related]
4. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322
[TBL] [Abstract][Full Text] [Related]
5. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy.
Van der Kwast T; Al Daoud N; Collette L; Sykes J; Thoms J; Milosevic M; Bristow RG; Van Tienhoven G; Warde P; Mirimanoff RO; Bolla M
Eur J Cancer; 2012 Jun; 48(9):1318-25. PubMed ID: 22405699
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of the presence of intraductal carcinoma of the prostate and bone metastasis in needle biopsy for prostate carcinoma patients with Grade Group 5.
Chen X; Yang Y; Wang W; Han B; Qi M; Geng S; Xu J; Zhang Q; Wang X; Chen S; Shi K; Ke X; Zhang J
Pathol Res Pract; 2020 Jan; 216(1):152693. PubMed ID: 31734052
[TBL] [Abstract][Full Text] [Related]
8. Prognostic parameter for high risk prostate cancer patients at initial presentation.
Kato M; Kimura K; Hirakawa A; Kobayashi Y; Ishida R; Kamihira O; Majima T; Funahashi Y; Sassa N; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2018 Jan; 78(1):11-16. PubMed ID: 29094384
[TBL] [Abstract][Full Text] [Related]
9. PTEN loss in intraductal carcinoma of the prostate has low incidence in Japanese patients.
Ito T; Takahara T; Taniguchi N; Yamamoto Y; Satou A; Ohashi A; Takahashi E; Sassa N; Tsuzuki T
Pathol Int; 2023 Nov; 73(11):542-548. PubMed ID: 37608749
[TBL] [Abstract][Full Text] [Related]
10. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
[TBL] [Abstract][Full Text] [Related]
11. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2020 Apr; 25(4):713-719. PubMed ID: 31820209
[TBL] [Abstract][Full Text] [Related]
12. The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival.
Trinh VQ; Sirois J; Benzerdjeb N; Mansoori BK; Grosset AA; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Ladouceur M; Fradet Y; Saad F; Trudel D
Prostate; 2018 Jul; 78(10):697-706. PubMed ID: 29603326
[TBL] [Abstract][Full Text] [Related]
13. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
[TBL] [Abstract][Full Text] [Related]
14. [The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer].
Zhao JG; Nie L; Chen XQ; Chen N; Zeng H
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):422-427. PubMed ID: 31142066
[No Abstract] [Full Text] [Related]
15. Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
Saeter T; Vlatkovic L; Waaler G; Servoll E; Nesland JM; Axcrona K; Axcrona U
Prostate; 2017 Jun; 77(8):859-865. PubMed ID: 28240424
[TBL] [Abstract][Full Text] [Related]
16. The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy.
Wang B; Fu Y; Chen M; Peng S; Marra G; Zhuang J; Zhang S; Guo H; Qiu X
Urol Oncol; 2024 Mar; 42(3):67.e9-67.e15. PubMed ID: 38233262
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate.
Trinh VQ; Benzerdjeb N; Chagnon-Monarque S; Dionne N; Delouya G; Kougioumoutzakis A; Sirois J; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Zorn KC; Fradet Y; Saad F; Taussky D; Trudel D
Radiat Oncol; 2019 Apr; 14(1):60. PubMed ID: 31018850
[TBL] [Abstract][Full Text] [Related]
18. Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma.
Shah RB; Yoon J; Liu G; Tian W
Histopathology; 2017 Nov; 71(5):693-702. PubMed ID: 28570007
[TBL] [Abstract][Full Text] [Related]
19. [SIGNIFICANCE OF INTRADUCTAL CARCINOMA OF THE PROSTATE IN POST-OPERATIVE BIOCHEMICAL RECURRENCE].
Sakamoto N; Ueda S; Mizoguchi H; Kawahara I; Kobayashi T; Hamaguchi M; Yoshikawa M
Nihon Hinyokika Gakkai Zasshi; 2017; 108(1):5-11. PubMed ID: 29367511
[TBL] [Abstract][Full Text] [Related]
20. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
Khani F; Epstein JI
Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]